Zibb.com: Sepracor Inc (Industry News & Blogs)

Sepracor Tenders Offer for 0% Convertible Senior Subordinated Not...

Thu, 29 Oct 2009 00:29:19 GMT

Sepracor Inc. has announced that it has commenced a tender offer to repurchase for cash up to all $279,000 aggregate principal amount of its outstanding 0 percent Convertible Senior Subordinated Notes due 2024. The tender offer will expire at 5 p.m., New York City time, on Tuesday, December 1,

Sepracor Announces Tender Offer for 0% Series B Convertible Senio...

Tue, 27 Oct 2009 01:00:00 GMT

Sepracor Inc. (â€œSepracorâ€) today announced that it has commenced a tender offer to repurchase for cash up to all $99,844,000 aggregate principal amount of its outstanding 0% Series B Convertible Senior Subordinated Notes due 2010 (the â€œNotesâ€). The t

Experts: Key drug facts often left off FDA labels (AP)

Wed, 21 Oct 2009 21:07:45 GMT

WASHINGTON (AP) -- Did you know that Lunesta will help you fall asleep just 15 minutes faster? Or that a higher dose of the osteoporosis drug

Sepracor deal closes, CEO in line for $11M

Wed, 21 Oct 2009 13:55:38 GMT

Japanese pharmaceutical giant Dainippon Sumitomo Pharma Co. has completed its $2.6 billion acquisition of Sepracor Inc., triggering change-in-control provisions at the local drug maker that could deliver roughly $11 million in pay and benefits to CEO Adrian Adams.

Dainippon Completes Sepracor Tender Offer

Wed, 14 Oct 2009 19:50:00 GMT

Pharmaceutical company said the first phase of its $2.6 billion tender offer for shares of drugmaker Sepracor Inc. was successful.

Royalty-Based Venture Financing, Born in Boston, Could Shake Up V...

Wed, 07 Oct 2009 11:03:19 GMT

Every once in a while, an investment model comes along that turns the innovation community on its head. The venture capital industry, still less than 50 years

Sepracor downgraded to "hold"

Wed, 16 Sep 2009 16:14:23 GMT

NEW YORK, September 16 (newratings.com) - Analysts at Sun Trust Robinson Humphrey downgrade Sepracor (ticker: SEPR) from "buy" to "hold." [more]

Dainippon Sumitomo Pharma to acquire Sepracor

Fri, 11 Sep 2009 04:00:00 GMT

In move designed to increase its position in North America, Dainippon Sumitomo Pharma (DSP, Japan) has agreed to acquire the specialty pharmaceutical company Sepracor (MA, USA) for $2.6 billion.

Sepracor Inc. Investor Lawsuits Seek To Bar The Deal

Wed, 09 Sep 2009 17:13:35 GMT

Sepracor Inc. Investor Lawsuits Seek To Bar The Deal. Lawsuits on behalf of investors of Sepracor Inc (Public, NASDAQ:SEPR)shares over alleged breach of fiduciary duty by the Sepracor Inc board of directors – Contact the Shareholders Foundation, Inc. at mail@shareholdersfoundation.com

Sepracor's Suitor Is Hard to Understand

Sun, 06 Sep 2009 11:47:11 GMT

Derek Lowe submits: Well, I

Dainippon Takes Over Sepracor

Fri, 04 Sep 2009 13:30:00 GMT

Dainippon Takes Over Sepracor. Acquisition: the purchase gives Japanese firm key U.S. presence

Sepracor vows to stay in Mass. - Boston Globe

Fri, 04 Sep 2009 03:46:17 GMT

Marlborough-based Sepracor Inc. vowed to maintain its Bay State operations, even after announcing a $2.6 billion deal yesterday to sell itself to Dainippon Sumitomo Pharma Co. of Japan.

Dainippon of Japan acquires US drug maker Sepracor

Thu, 03 Sep 2009 22:35:05 GMT

Dainippon Sumitomo Pharma Co. is acquiring U.S. drug maker Sepracor Inc., which makes insomnia drug Lunesta, for about $2.6 billion in an effort to expand in the U.S. market, both sides said Thursday.

Sepracor gets a healthy buyout

Thu, 03 Sep 2009 18:00:00 GMT

Filed under: Deals, Japan

Dainippon To Acquire Sepracor

Thu, 03 Sep 2009 14:50:00 GMT

Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. have entered into a definitive agreement under which DSP will acquire Sepracor for approximately $2.6 billion in cash.

Japanese firm buys Sepracor for $2.6B

Thu, 03 Sep 2009 14:14:04 GMT

Japanese drug maker Dainippon Sumitomo Pharma Co. LTD has acquired Sepracor, the Marlborough, Mass., biotechnology company most famous for its sleep aid Lunesta, in an all cash deal worth about $2.6 billion.

Dainippon Sumitomo to Buy Sepracor for $2.6 Billion - Bloomberg

Thu, 03 Sep 2009 14:07:42 GMT

[bn:WBTKR=4506:JT] Dainippon Sumitomo Pharma Co. [] agreed to buy [bn:WBTKR=SEPR:US] Sepracor Inc. [] for $2.6 billion to gain a U.S. sales force and experimental treatments in the world’s biggest drug market.

Dainippon Sumimoto / Sepracor (at FT.com)

Thu, 03 Sep 2009 13:40:19 GMT

Long content to slug it out in their fragmented, $70bn-a-year domestic market, Japanese drugmakers have had something of a coming-out party lately. Dainippon Sumitomo Pharma’s $2.

Japanese company acquires U.S. drug maker Sepracor

Thu, 03 Sep 2009 12:45:00 GMT

Dainippon acquires maker of Lunesta for $2.6-billion; gains access to established drugs, North American sales network

Dainippon of Japan acquires US drug maker Sepracor

Thu, 03 Sep 2009 12:25:13 GMT

Japanese drug company Dainippon Sumitomo Pharma Co. is acquiring U.S. drug maker Sepracor Inc. for about $2.6 billion in an effort to expand in the U.S. market, both sides said Thursday.

Dainippon Sumitomo Pharma Co., Ltd. to Buy U.S. Drug Firm Sepraco...

Thu, 03 Sep 2009 12:00:00 GMT

OSAKA, Japan & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.

Nomura, JP Morgan bag plum roles in Dainippon deal

Thu, 03 Sep 2009 11:42:28 GMT

By Junko Fujita TOKYO, Sept 3 (Reuters) - Nomura Holdings cemented its position at the top of the M&A league tables in Japan by bagging a mandate to advise Dainippon Sumitomo Pharma

Dainippon to Buy US Drug Firm Sepracor For $2.6 Billion - New Yor...

Thu, 03 Sep 2009 11:00:32 GMT

BOSTON/TOKYO (Reuters) - Dainippon Sumitomo Pharma Co Ltd agreed on Thursday to buy U.S. drugmaker Sepracor Inc for $2.6 billion, giving the Japanese firm a big, local sales force in the world's largest drugs market.

Dainippon of Japan acquires US drug maker Sepracor

Thu, 03 Sep 2009 10:34:04 GMT

Japanese drug company Dainippon Sumitomo Pharma Co. is acquiring U.S. drug maker Sepracor Inc. for about $2.6 billion in an effort to expand in the U.S. market, both sides said Thursday. The deal is through a tender offer at a price of $23 per share, a 27.6...

Dainippon to Buy Drug Firm Sepracor for $2.6B

Thu, 03 Sep 2009 10:29:39 GMT

BOSTON/TOKYO--Dainippon Sumitomo Pharma Co Ltd agreed on Thursday to buy U.S. drugmaker Sepracor Inc for $2.6 billion, giving the Japanese firm a big, local sales force in the world's largest drugs market.